Literature DB >> 28759094

Conversion of Sugar to Fat: Is Hepatic de Novo Lipogenesis Leading to Metabolic Syndrome and Associated Chronic Diseases?

Jean-Marc Schwarz, Michael Clearfield, Kathleen Mulligan.   

Abstract

Epidemiologic studies suggest a link between excess sugar consumption and obesity, fatty liver disease, metabolic syndrome, and type 2 diabetes mellitus. One important pathway that may link these metabolic diseases to sugar consumption is hepatic conversion of sugar to fat, a process known as de novo lipogenesis (DNL). Mechanistic studies have shown that diets high in simple sugars increase both DNL and liver fat. Importantly, removal of sugar from diets of children with obesity for only 9 days consistently reduced DNL and liver fat and improved glucose and lipid metabolism. Although the sugar and beverage industries continue to question the scientific evidence linking high-sugar diets to metabolic diseases, major health organizations now make evidence-based recommendations to limit consumption of simple sugars to no more than 5% to 10% of daily intake. Clear recommendation about moderating sugar intake to patients may be an important nonpharmacologic tool to include in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28759094     DOI: 10.7556/jaoa.2017.102

Source DB:  PubMed          Journal:  J Am Osteopath Assoc        ISSN: 0098-6151


  5 in total

Review 1.  A High-Sugar Diet Consumption, Metabolism and Health Impacts with a Focus on the Development of Substance Use Disorder: A Narrative Review.

Authors:  Kacper Witek; Karolina Wydra; Małgorzata Filip
Journal:  Nutrients       Date:  2022-07-18       Impact factor: 6.706

2.  Cardiovascular Biomarkers in Association with Dietary Intake in a Longitudinal Study of Youth with Type 1 Diabetes.

Authors:  Namrata Sanjeevi; Leah M Lipsky; Tonja R Nansel
Journal:  Nutrients       Date:  2018-10-19       Impact factor: 5.717

3.  Thioredoxin Interacting Protein Is Required for a Chronic Energy-Rich Diet to Promote Intestinal Fructose Absorption.

Authors:  Anu Shah; Sezin Dagdeviren; Jordan P Lewandowski; Angela B Schmider; Elisabeth M Ricci-Blair; Niranjana Natarajan; Henna Hundal; Hye Lim Noh; Randall H Friedline; Charles Vidoudez; Jason K Kim; Amy J Wagers; Roy J Soberman; Richard T Lee
Journal:  iScience       Date:  2020-09-02

4.  Danggui-Shaoyao-San Improves Gut Microbia Dysbiosis and Hepatic Lipid Homeostasis in Fructose-Fed Rats.

Authors:  Jing Yin; Jiaxi Lu; Peng Lei; Mingshuai He; Shengjie Huang; Jialin Lv; Yan Zhu; Zhidong Liu; Miaomiao Jiang
Journal:  Front Pharmacol       Date:  2021-07-13       Impact factor: 5.810

5.  Fatty Acid Synthase Inhibitor Platensimycin Intervenes the Development of Nonalcoholic Fatty Liver Disease in a Mouse Model.

Authors:  Meng Su; Danfeng Cao; Zhe Wang; Yanwen Duan; Yong Huang
Journal:  Biomedicines       Date:  2021-12-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.